The company’s product candidate portfolio comprises BCT-100 and BCT-200, both pegylated recombinant human arginase 1 (pegArg1), are arginine depleting agents that retard tumor growth and ultimately lead to cancer death. BCT-100 is currently in phase I clinical trial in the US for the treatment of arginine-auxotrophic solid cancers and phase II clinical trials in United Kingdom for the treatment of acute myeloid leukemia (AML) in combination with low dose cytarabine in elderly patients and in sarcomas, AML and neuroblastoma in pediatric patients.
